Pemigatinib Inhibitor

Name: Pemigatinib Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5753658
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5753658

Pemigatinib is an orally active, selective inhibitor of FGFR(IC50s of 0.4nM, 0.5nM, 1.2nM, 30nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively). More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Pemigatinib, Inhibitor

Full Product Name

Pemigatinib

Product Synonym Names

INCB054828

Form/Format

Powder

Purity/Purification

99.4%

Preparation and Storage

Store at -20°C.

Molecular Weight

487.5

Solubility

DMSO: 40mg/mL (82.05mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)

Molecular Formula

C24H27F2N5O4

CAS Number

1513857-77-6

Targets (IC50)

FGFR

In Vitro

In cells expressing FGFR2-CLIP1 fusion are sensitive to Pemigatinib (INCB054828; IC50 value of 10.16nM)[3].

Analytical Data

HNMR: Consistent with structure
HPLC: Consistent with structure
Conclusion: The test result is consistent with structure

Preparing Stock Solutions

1mg/5mg,10mg
1mM: (1mg) 2.0513, (5mg) 10.2564, (10mg) 20.5128
5mM:(1mg) 0.4103, (5mg) 2.0513, (10mg) 4.1026
10mM: (1mg)0.2051, (5mg) 1.0256, (10mg) 2.00513
50mM: (1mg) 0.041, (5mg) 0.2051, (10mg) 0.4103
Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Product Categories/Family for Pemigatinib, inhibitor

Angiogenesis; FGFR; Tyrosine Kinase/Adaptors

Product References and Citations for Pemigatinib, inhibitor

Arudra K, et al. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment,of Wilms tumor. J Cutan Pathol. 2018 Oct;45(10):786-790.
Arudra K, et al. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment,of Wilms tumor. J Cutan Pathol. 2018 Oct;45(10):786-790.
Roskoski R Jr, et al. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment,of cancers including those of the urinary bladder. Pharmacol Res. 2020 Jan;151:104567.
Roskoski R Jr, et al. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment,of cancers including those of the urinary bladder. Pharmacol Res. 2020 Jan;151:104567.
Krook MA, et al. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. Cold Spring Harb Mol Case Stud. 2019 Aug 1;5(4).
Krook MA, et al. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. Cold Spring Harb Mol Case Stud. 2019 Aug 1;5(4).

Other Notes

Small volumes of Pemigatinib, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Pemigatinib purchase

MBS5753658 is an inhibitor targeting Pemigatinib.